Anti-Fibrotic Drug Recruiting Patients Across the Country for Phase 2 Clinical Trial

Researchers are currently recruiting patients for the PROMOTE study, a phase 2 trial of PRM-151 in subjects with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia. PRM-151 is a recombinant form of pentraxin-2 (PTX-2), a protein that circulates in the blood stream that helps to regulate tissue repair.

The MPN Research Foundation